Search

MannKind Corp

Suletud

SektorTervishoid

3.51 2.93

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.51

Max

3.54

Põhinäitajad

By Trading Economics

Sissetulek

5.7M

13M

Müük

1.6M

78M

P/E

Sektori keskmine

39.2

34.393

Kasumimarginaal

16.793

Töötajad

403

EBITDA

8.3M

27M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+163.92% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-316M

1.2B

Eelmine avamishind

0.58

Eelmine sulgemishind

3.51

Uudiste sentiment

By Acuity

14%

86%

21 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

MannKind Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. aug 2025, 21:43 UTC

Tulu

Constellation Software 2Q Revenue Rises, Profit Shrinks

8. aug 2025, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8. aug 2025, 22:42 UTC

Omandamised, ülevõtmised, äriostud

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8. aug 2025, 21:31 UTC

Market Talk
Tulu

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8. aug 2025, 21:00 UTC

Tulu

Constellation Software 2Q Rev $2.84B >CSU.T

8. aug 2025, 21:00 UTC

Tulu

Constellation Software 2Q Net $56M >CSU.T

8. aug 2025, 21:00 UTC

Tulu

Constellation Software 2Q EPS $2.66 >CSU.T

8. aug 2025, 20:55 UTC

Market Talk

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8. aug 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

8. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. aug 2025, 20:35 UTC

Market Talk

Mexico's Industrial Production Seen Higher in June -- Market Talk

8. aug 2025, 20:28 UTC

Tulu

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8. aug 2025, 20:28 UTC

Tulu

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8. aug 2025, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8. aug 2025, 20:08 UTC

Tulu

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8. aug 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8. aug 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8. aug 2025, 19:13 UTC

Market Talk

Oil Futures End Volatile Week Lower -- Market Talk

8. aug 2025, 18:21 UTC

Market Talk

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8. aug 2025, 17:27 UTC

Tulu

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8. aug 2025, 17:09 UTC

Tulu

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8. aug 2025, 17:03 UTC

Tulu

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8. aug 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

8. aug 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. aug 2025, 15:53 UTC

Omandamised, ülevõtmised, äriostud

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8. aug 2025, 15:51 UTC

Omandamised, ülevõtmised, äriostud

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8. aug 2025, 15:50 UTC

Omandamised, ülevõtmised, äriostud

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8. aug 2025, 15:48 UTC

Omandamised, ülevõtmised, äriostud

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8. aug 2025, 15:47 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8. aug 2025, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Võrdlus sarnastega

Hinnamuutus

MannKind Corp Prognoos

Hinnasiht

By TipRanks

163.92% tõus

12 kuu keskmine prognoos

Keskmine 9.29 USD  163.92%

Kõrge 12 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi MannKind Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.079 / 4.323Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

21 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.